IP Verse

Medicaments For Increasing Endogenous Erythropoietin (Epo) - EP2298301

The patent EP2298301 was granted to Fibrogen on Nov 16, 2022. The application was originally filed on Dec 6, 2002 under application number EP10181796A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2298301

FIBROGEN
Application Number
EP10181796A
Filing Date
Dec 6, 2002
Status
Patent Maintained As Amended
Oct 14, 2022
Grant Date
Nov 16, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AKEBIA THERAPEUTICSApr 3, 2019JONES DAYADMISSIBLE

Patent Citations (54) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0650960
DESCRIPTIONEP0650961
DESCRIPTIONUS4558006
DESCRIPTIONUS4667016
DESCRIPTIONUS5474796
DESCRIPTIONUS5605662
DESCRIPTIONUS5607954
DESCRIPTIONUS5610172
DESCRIPTIONUS5620995
DESCRIPTIONUS5620996
DESCRIPTIONUS5658933
DESCRIPTIONUS5719164
DESCRIPTIONUS5726305
DESCRIPTIONUS5916898
DESCRIPTIONUS6020350
DESCRIPTIONUS6093730
DESCRIPTIONUS6200974
DESCRIPTIONWO0050390
DESCRIPTIONWO9525111
DESCRIPTIONWO9535505
DESCRIPTIONWO9921860
EXAMINATIONDE10010423
EXAMINATIONEP0765871
EXAMINATIONEP0911340
EXAMINATIONEP1463823
EXAMINATIONWO9741103
OPPOSITIONCA2134866
OPPOSITIONDE10010423
OPPOSITIONDE10010425
OPPOSITIONDE10010426
OPPOSITIONDE10010430
OPPOSITIONEP0650960
OPPOSITIONEP0650961
OPPOSITIONEP0765871
OPPOSITIONEP0911340
OPPOSITIONEP1633333
OPPOSITIONUS5607954
OPPOSITIONUS5610172
OPPOSITIONUS5620995
OPPOSITIONUS5620996
OPPOSITIONUS5658933
OPPOSITIONUS5719164
OPPOSITIONUS5726305
OPPOSITIONUS6020350
OPPOSITIONUS6093730
OPPOSITIONWO0164652
OPPOSITIONWO02074981
OPPOSITIONWO03049686
OPPOSITIONWO03053997
OPPOSITIONWO2008002576
OPPOSITIONWO9741103
OTHEREP1463823
OTHEREP1633333
SEARCHDE10010430

Non-Patent Literature (NPL) Citations (120) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ARAVIND; KOONIN, GENOME BIOL, (2001), vol. 2-
DESCRIPTION- BICKEL ET AL., HEPATOLOGY, (1998), vol. 28, pages 404 - 411-
DESCRIPTION- BIOCHEM J, (1985), vol. 229, pages 127 - 133-
DESCRIPTION- BRINES ET AL., PROC NATL ACAD SCI USA, (2000), vol. 97, pages 10526 - 10531-
DESCRIPTION- BRUICK; MCKNIGHT, SCIENCE, (2001), vol. 294, pages 1337 - 1340-
DESCRIPTION- CALAPAI ET AL., EUR J PHARMACOL, (2000), vol. 401, pages 349 - 356-
DESCRIPTION- CELIK ET AL., PROC NATL ACAD SCI USA, (2002), vol. 99, pages 2258 - 2263-
DESCRIPTION- COLOWICK, S. ET AL., Methods In Enzymology, ACADEMIC PRESS, INC.-
DESCRIPTION- CRISWELL ET AL., J APPL TOXICOL, (2000), vol. 20, pages 25 - 34-
DESCRIPTION- CROSBY, AMER J THERAP, (2002), vol. 9, pages 371 - 376-
DESCRIPTION- CUNLIFFE ET AL., BIOCHEM J, (1986), vol. 240, pages 617 - 619-
DESCRIPTION- DUPUY ET AL., GENOMICS, (2000), vol. 69, pages 348 - 54-
DESCRIPTION- EPSTEIN ET AL., CELL, (2001), vol. 107, pages 43 - 54-
DESCRIPTION- FRANKLIN ET AL., BIOCHEM J, (2001), vol. 353, pages 333 - 338-
DESCRIPTION- FRIEDMAN ET AL., PROC NATL ACAD SCI USA, (2000), vol. 97, pages 4736 - 4741-
DESCRIPTION- Handbook of Experimental Immunology, BLACKWELL SCIENTIFIC PUBLICATIONS, (1986), vol. I-IV-
DESCRIPTION- IVAN; KAELIN, SCIENCE, (2001), vol. 292, pages 464 - 468-
DESCRIPTION- JACKSON; HUNT, METHODS ENZYMOL, (1983), vol. 96, pages 50 - 74-
DESCRIPTION- JACOBSON ET AL., NATURE, (1957), vol. 179, pages 633 - 634-
DESCRIPTION- JIA ET AL., PROC NATL ACAD SCI USA, (1994), vol. 91, pages 7227 - 7231-
DESCRIPTION- JIANG ET AL., J BIOL CHEM, (1997), vol. 272, pages 19253 - 19260-
DESCRIPTION- KAULE; GUNZLER, ANAL BIOCHEM, (1990), vol. 184, pages 291 - 297-
DESCRIPTION- KIVIRIKKO, EMBO J, (1997), vol. 16, pages 1173 - 1180-
DESCRIPTION- KIVIRIKKO; MYLLYHARJU, MATRIX BIOL, (1998), vol. 16, pages 357 - 368-
DESCRIPTION- LANDO ET AL., GENES DEV, (2002), vol. 16, pages 1466 - 1471-
DESCRIPTION- LANDO ET AL., SCIENCE, (2002), vol. 295, pages 858 - 861-
DESCRIPTION- LIN ET AL., PROC NATL ACAD SCI USA, (1985), vol. 82, pages 7580 - 7584-
DESCRIPTION- MAHON ET AL., GENES DEV, (2001), vol. 15, pages 2675 - 2686-
DESCRIPTION- MAJAMAA ET AL., BIOCHEM J, (1985), vol. 229, pages 127 - 133-
DESCRIPTION- MAJAMAA ET AL., EUR J BIOCHEM, (1984), vol. 138, pages 239 - 45-
DESCRIPTION- MAJAMAA, EUR J BIOCHEM, (1984), vol. 138, pages 239 - 245-
DESCRIPTION- Molecular Cloning: A Laboratory Manual, 2nd edition,, COLD SPRING HARBOR LABORATORY PRESS, (1989), vol. I-III-
DESCRIPTION- NEMOTO ET AL., KIDNEY INT, (2001), vol. 59, pages 246 - 51-
DESCRIPTION- PALMERINI ET AL., J CHROMATOGR, (1985), vol. 339, pages 285 - 292-
DESCRIPTION- PELHAM; JACKSON, EUR J BIOCHEM, (1976), vol. 67, pages 247 - 256-
DESCRIPTION- PRIYADARSHI ET AL., KIDNEY INT, (2002), vol. 61, pages 542 - 546-
DESCRIPTION- RENCRICCA ET AL., BLOOD, (1970), vol. 36, pages 764 - 71-
DESCRIPTION- SAKANAKA, PROC NATL ACAD SCI U S A, (1998), vol. 95, pages 4635 - 4640-
DESCRIPTION- SEKI ET AL., CHEM ABSTRACTS, (1974), vol. 81, no. 21, page 424-
DESCRIPTION- SIREN ET AL., PROC NATL ACAD SCI USA, (2001), vol. 98, pages 4044 - 404-
DESCRIPTION- SRINIVAS ET AL., BIOCHEM BIOPHYS RES COMMUN, (1999), vol. 260, pages 557 - 561-
DESCRIPTION- TAN ET AL., KIDNEY INT, (1996), vol. 50, pages 1958 - 64-
DESCRIPTION- TAYLOR, GENE, (2001), vol. 275, pages 125 - 132-
DESCRIPTION- VAZIRI ET AL., AM J PHYSIOL, (1994), vol. 266, pages F360 - 6-
EXAMINATION- WARSHAKOON N C ET AL, "Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 21, ISSN 0960-894X, (20061101), pages 5616 - 5620, (20061101), XP027966145-
EXAMINATION- HOFER T ET AL, "Oxygen sensing, HIF-1[alpha] stabilization and potential therapeutic strategies", PFLUEGERS ARCHIV: EUROPEAN JOURNAL OF PHYSIOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 443, no. 4, doi:10.1007/S00424-001-0759-8, ISSN 0031-6768, (20140430), pages 503 - 507, (20140430), XP036392387
OPPOSITION- Agreement Gusnzler-Pukall-
OPPOSITION- Agreement Neff-
OPPOSITION- Akebia GSK trial skeleton in UK litigation-
OPPOSITION- Appendix A to First declaration Prof. Erstling in EP 2242512-
OPPOSITION- Baringhaus - 3D QSAR of prolyl 4-hydoxylase inhibitors-
OPPOSITION- Data compilation (collagen prolyl 4-hydroxylase inhibition)-
OPPOSITION- Data compilation for compounds across the scope of formula (1)-
OPPOSITION- Data showing effect of concentration-
OPPOSITION- Decision by the Opposition Division in case EP 1 463 823-
OPPOSITION- Decision from the UK High Court of Justice (20.04.2020)-
OPPOSITION- Declaration of Dr. Franklin (including Annexes 1-11)-
OPPOSITION- Declaration of Dr. Semenza (including Annexes A-Q)-
OPPOSITION- Declaration of Dr. Szczech (including Annexes A-F)-
OPPOSITION- Declaration of Dr. Walkinshaw-
OPPOSITION- Declaration of J. Patrick Elsevier, Ph.D. and Appendices A to E-
OPPOSITION- English translation of DE 100 10 430 A1 (Espacenet)-
OPPOSITION- Epstein, A.C.R. et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation, Cell, 107, 43-54-
OPPOSITION- Erslev and Besarab, Kidney International, Vol. 51 (1997),pp. 622-630-
OPPOSITION- Experimental report regarding compounds from D12-
OPPOSITION- Extract from Formula (I) showing Blocks-
OPPOSITION- Fed. Circuit: Bd. of Trustees of Leland Stanford Junior Univ. v. Roche Molecular Sys.-
OPPOSITION- Fed. Circuit: IP Venture vs. ProStar-
OPPOSITION- First declaration Prof. Erstling in EP 2242512-
OPPOSITION- Friedman et al-
OPPOSITION- Fujifilm and others vs AbbVie Biotechnology Limited, [2017]EWHC 395 (PAT)-
OPPOSITION- Full version of D45-
OPPOSITION- Full version of D47-
OPPOSITION- Further compound data (pairs)-
OPPOSITION- Further compound data (table of compounds from IC50 analysis)-
OPPOSITION- G: Bruick, R. K. and McKnight, S.L. (November 9, 2001), A conserved family of Prolyl-4-Hydroxylases that modify HIF, Science, 294: 1337-1340.-
OPPOSITION- Giaccia et al. (2003) Nature Reviews Drug Discovery 2:1-9-
OPPOSITION- Grounds of appeal in opposition proceedings relating to EP 1463823 A2-
OPPOSITION- Gunzler - Prolyl 4-hydroxylase inhibitors-
OPPOSITION- Hofer et al: “Oxygen sensing, HIF-1 alpha stabilization and potential therapeutic strategies", (2002) Eur J Physiol. 443:503-507-
OPPOSITION- Ivan et al: “Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor”, PNAS, vol. 99, no. 21, 15 October 2002-
OPPOSITION- Ivan et al., “HIFalpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for 02 Sensing", Science, vol 292, 20 April 2001, pages 464-8.-
OPPOSITION- Jaakkola et al., “Targeting of HIF-a to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation”, Science, 20 April 2001, Vol. 292, 468-472.-
OPPOSITION- Jelkmann W. et al: "Erythropoietin in the control of red cell production.", Annals of Anatomy vol. 178, no. 5, October 1996(1996-10), pages 391-403-
OPPOSITION- Johnson and Feehally - Comprehensive Clinical Nephrology-
OPPOSITION- Joint Status Report and Appendices 1,2 and 3-
OPPOSITION- Kallio Pekka et. al.: "Regulation of the hypoxia-inducible transcription factor 1 alpha by the ubiquitin-proteasome pathway", Journal of Biological Chemistry, vol. 274, no. 10, 5, March 1999, pages 6519-6525-
OPPOSITION- Lipinski-
OPPOSITION- Majamaa et al. Biochem J (1985) 229 pp. 127-133-
OPPOSITION- Majamaa et al. Eur. J. Biochem. (1984) vol. 138, pp. 239-245-
OPPOSITION- Masson et al: "Independent function of two destruction domains in hypoxiainducible factor-alfa chains activated by prolyl hydroxylation", EMBO Journal, vol. 20, no. 18, 1 January 2001, pages 5197-5206-
OPPOSITION- Medscape article - Chronic Kidney Disease-
OPPOSITION- Mole, Life, 52:43-47, 2001-
OPPOSITION- Opposition Division's decision in EP1633333 (including the main request in that decision, and the list of cited documents)-
OPPOSITION- Poster presentation at Keystone Conference, January 15-20, 2008-
OPPOSITION- Preliminary opinion for EP2324834-
OPPOSITION- Roach et al, “Hypoxia, From Genes to the Bedside” in Advances in Experimental Medicine and Biology, Volume 502, London, Moscow, August 2001, 445 pages-
OPPOSITION- Schrier - Diseases of the Kidney-
OPPOSITION- Second declaration Prof. Erstling in EP 2242512-
OPPOSITION- Semenza (2001) Cell 107:1-3-
OPPOSITION- Semenza (2001) Trends in Molecular Medicine 7(8):345-350-
OPPOSITION- Semenza, Genes Dev 14, 1983-91. (2000).-
OPPOSITION- S. Salceda: "Hypoxia-inducible Factor 1 alpha (HIF-1 alpha)Protein is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions. Its Stabilization by hypoxia depends on redox-induced changes", Journal of Biological Chemistry, vol. 272, no. 36, 5 September 1997, pages 22642-22647-
OPPOSITION- Test data filed by the opponent in the EP '823 case on 05.12.2013 as Annex 022-
OPPOSITION- Transcript of excerpt of P. Ratcliffe speech-
OPPOSITION- Transfer agreement-
OPPOSITION- UK Court of Appeal decision-
OPPOSITION- Warshakoon et al., “Design and synthesis of substituted pyridine derivatives as HIF-la prolyl hydroxylase inhibitors", Bioorganic & Medicinal Chermistry Letters, 2006, Vol. 16, 5616-5620-
OPPOSITION- Wenger et al: "Oxygen(es), and the hypoxia-inducible factor-1”, Biol. Chem. July 1997, Vol. 378, pp. 609-616-
SEARCH[ ] - ANNALS OF ANATOMY = ANATOMISCHER ANZEIGER : OFFICIAL ORGAN OF THE ANATOMISCHE GESELLSCHAFT OCT 1996 LNKD- PUBMED:8931850, (199610), vol. 178, no. 5, ISSN 0940-9602, pages 391 - 403-
SEARCH[ ] - BIOLOGICAL CHEMISTRY JUL 1997 LNKD- PUBMED:9278140, (199707), vol. 378, no. 7, ISSN 1431-6730, pages 609 - 616-
SEARCH- WENGER R H ET AL, "Oxygen(es) and the hypoxia-inducible factor-1.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199707), Database accession no. NLM9278140, XP002684806 [Y] 1-12,14-18 * abstract *-
SEARCH- EPSTEIN A C R ET AL, "C. ELEGANS EGL-9 AND MAMMALIAN HOMOLOGS DEFINE A FAMILY OF DIOXYGENASES THAT REGULATE HIF BY PROLYL HYDROXYLATION", CELL, CELL PRESS, US, (20011005), vol. 107, no. 1, doi:10.1016/S0092-8674(01)00507-4, ISSN 0092-8674, pages 43 - 54, XP008046407 [Y] 1-12,14-18 * abstract * * page 43 - page 44, column l, paragraph 1 * * page 47, column l, paragraph 2 - page 48, column l, paragraph 1 * * paragraph 1 of "discussion"; page 51, column l * * page 52, column r, paragraph 2 - paragraph 3 *
SEARCH- JELKMANN W ET AL, "Erythropoietin in the control of red cell production.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199610), Database accession no. NLM8931850, XP002684805 [Y] 1-12,14-18 * abstract *
SEARCH- S. SALCEDA, "Hypoxia-inducible Factor 1alpha (HIF-1alpha ) Protein Is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions. ITS STABILIZATION BY HYPOXIA DEPENDS ON REDOX-INDUCED CHANGES", JOURNAL OF BIOLOGICAL CHEMISTRY, (19970905), vol. 272, no. 36, doi:10.1074/jbc.272.36.22642, ISSN 0021-9258, pages 22642 - 22647, XP055040278 [A] 1 * abstract * * page 22642 *
SEARCH- KALLIO PEKKA J ET AL, "Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (19990305), vol. 274, no. 10, doi:10.1074/JBC.274.10.6519, ISSN 0021-9258, pages 6519 - 6525, XP002146028 [A] 1 * abstract * * page 6524, column l, paragraph 2 - paragraph 3 *
SEARCH- MASSON N ET AL, "Independent function of two destruction domains in hypoxia-inducible factor-alfa chains activated by prolyl hydroxylaTIOn", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (20010101), vol. 20, no. 18, doi:10.1093/EMBOJ/20.18.5197, ISSN 0261-4189, pages 5197 - 5206, XP002253782 [A] 1 * abstract * * page 5201, column r, paragraph 2 - paragraph 3 *
SEARCH- P. JAAKKOLA ET AL, "Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation", SCIENCE, (20010420), vol. 292, no. 5516, doi:10.1126/science.1059796, ISSN 0036-8075, pages 468 - 472, XP055040289 [Y] 1-12,14-18 * abstract * * page 470, column 1, paragraph 3 - paragraph 4 * * page 471, column 1, paragraph 1 - column 2, paragraph 1 * * page 471, column 3, paragraph 3 *
SEARCH- IVAN MIRCEA ET AL, "HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20010420), vol. 292, no. 5516, doi:10.1126/SCIENCE.1059817, ISSN 0036-8075, pages 464 - 468, XP002207795 [Y] 1-12,14-18 * abstract * * page 467, column l, paragraph 2 - column r, paragraph 4 *
SEARCH- BRUICK RICHARD K ET AL, "A conserved family of prolyl-4-hydroxylases that modify HIF", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20011109), vol. 294, no. 5545, doi:10.1126/SCIENCE.1066373, ISSN 0036-8075, pages 1337 - 1340, XP002433273 [Y] 1-12,14-18 * abstract * * page 1337 * * page 1337, column 3, paragraph 3 - paragraph 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents